Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chikungunya vaccine (Hawaii Biotech)
- Development stage
- Preclinical
- Lead developer
- Hawaii Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Hawaii Biotech's chikungunya vaccine is a recombinant subunit vaccine candidate developed in collaboration with Baylor College of Medicine for the prevention of chikungunya virus (CHIKV) infection. The vaccine utilizes Hawaii Biotech's proprietary protein expression platform, which employs stable insect cell lines to produce recombinant CHIKV viral antigens. It is designed to elicit high titers of virus-neutralizing antibodies. In preclinical research supported by a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine candidate demonstrated the ability to prevent viral replication in immunocompetent mice and provide protection against lethal challenge in immunocompromised animal models.
- Other names
- Hawaii Biotech chikungunya vaccineCHIKV recombinant subunit vaccineHawaii Biotech CHIKV vaccine
02
Targets
CHIKV structural polyprotein (Chikungunya virus structural polyprotein)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)CHIKV E2/E1 (Chikungunya virus envelope protein)
Beyond the preview
Go deeper on chikungunya vaccine (Hawaii Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chikungunya vaccine (Hawaii Biotech).